Navigation Links
Infinity and MedImmune Announce Updated Data On Ipi-504 to be,Presented At ASCO

CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinical data on IPI-504 in a Phase I trial in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas (STS), will be presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 1-5, 2007 at McCormick Place in Chicago, Ill. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated as a water-soluble, intravenous formulation in two disease-focused clinical trials involving patients with GIST/STS and non-small cell lung cancer (NSCLC).

* A poster entitled, "Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy," (Poster Number 1, Abstract No: 3530) will be presented on Saturday, June 2, 2007 from 2:00-6:00 p.m. CDT in Room S102a.

* A poster entitled, "Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial," (Poster Number 8, Abstract No: 10023) will be presented on Monday, June 4, 2007 from 2:00-6:00 p.m. CDT in Room S103a.

About IPI-504

IPI-504 is a small molecule drug candidate being developed jointly by Infinity and MedImmune. IPI-504 has been well tolerated in its ongoing Phase I studies and has shown promising biological activity in a Phase I clinical trial in patients with relapsed, refractory, Gleevec(r)-resistant GIST. IPI-504 is also being evaluated in a Phase I/II clinical trial in patients with advanced NSCLC. In preclinical studies, IPI-504 has been
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Infinity and MedImmune Announce Updated Data Ipi Presented ASCO
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/23/2014)... Hopkins scientists report that rats exposed to high-energy particles, ... space mission, show lapses in attention and slower reaction ... low dose ranges. , The cognitive impairments which ... the animals appear to be linked to protein ... if found to hold true in humans, suggest it ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... area of the gastro-intestinal tract has long been considered ... at the Sahlgrenska Academy have used refined microscopic techniques ... inner surface of the gastro-intestinal tract is only as ... Fndriks. , The digestive tract, which passes from the ... has a length of about 5 meters in a ...
(Date:4/23/2014)... predict which patients might suffer potentially fatal side-effects from ... assesses brain scans using pattern recognition software similar to ... been developed by researchers at Imperial College London. Results ... which used the software are published in the journal ... 15 million people each year worldwide. Ischemic strokes are ...
(Date:4/23/2014)... Bethesda, MD (April 23, 2014) The American ... announce the 2014 AGA Research Scholars. The AGA ... young investigators to develop independent and productive research ... Research Scholar Awards fund an additional year allowing ... is committed to supporting junior faculty who are ...
Breaking Medicine News(10 mins):Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:AGA announces 2014 Class of AGA Research Scholars 2
... Supreme Court today issued notices to the Centre and Medical Council ... by doctors. // ,A bench of Justice Arijit Pasayat ... respond to the PIL filed by People for Better Treatment, within ... file its rejoinder to the replies of Centre and MCI., ...
... Lebanon will not have to wait for access to public ... it will waive the mandatory three-month waiting period for OHIP ... the Health Minister George Smitherman the evacuees have undergone a ... the "health care they need when they need it the ...
... deaths in municipal hospitals in Mumbai from Saturday morning ... and another of suspected leptospirosis.// ,The Brihanmumbai ... on Sunday with various diseases — 208 with fever, ... vomiting,; 10 of 'suspected dengue', 19 with jaundice and ...
... BMA Cymru Wales' response to growing concerns amongst Welsh ... ,Launching the guidance document, chairman of ... “Unwanted and unprofessional behaviour in the workplace that is ... suffer from bullying and harassment like any other profession. ...
... the country do not disclose their status at workplaces ... ,"Seventy-four per cent of the employees have ... the remaining 26 per cent who have disclosed their ... the hands of the employer," a UNDP-NACO-NCAER report on ...
... organizations urge anyone over age 65 to get yearly ... preventing flu and its complications among older adults, according ... ,Similarly, there is a little evidence that vaccinating healthcare ... study found. ,The reviews appear in the ...
Cached Medicine News:Health News:Doctors' Bid to End Bullying and Harassment in the Workplace 2Health News:Only Modest Benefit of Flu Shots Among Older Adults 2Health News:Only Modest Benefit of Flu Shots Among Older Adults 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: